# HBL Hadasit Bio Holdings

> HBL Hadasit Bio Holdings is a VC fund backing Biotechnology and Medical. See 11 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Jerusalem, Israel
- Total investments: 11
- Last investment: Jun 2021
- Lead investor: 9%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/hadasit-bio-holdings-ltd-
- X (Twitter): http://twitter.com/HadasitBio
- Website: http://www.hbl.co.il

HBL Hadasit Bio Holdings is a VC fund in Jerusalem focused on Biotechnology and Medical. Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE : HDST ) and recently on the OTC (OTCBB : HADSY ) in order to allow public participation in the highly promising field of biotechnology.It serves as a precedent in biotech financing - for the first time, public investment is allowed toparticipate in a holding entity including companies based on IP generated by Israel’s foremost medical research center – Hadassah University Hospital ("HU").In addition to the public holdings (54%) – including major Israeli institutional investors, HBL is held by Hadasit (www.hadasit.co.il) (36%) and Consensus Business Group (http://www.consensusbusiness.com) (10%). The traded stock, as a unique investment vehicle, provides investment exposure to a select cluster of 6 biotech companies - all based on inventions developed and owned by HU.HBL is a publicly traded subsidiary of Hadasit Ltd. – the technology transfer company of the Hadassah University Hospital in Jerusalem, Israel. Hadasit was established for the purpose of promoting and commercializing the intellectual property (IP) and R&D capabilities generated by Hadassah, aimed at finding solutions to problems faced by modern medicine.

## Contacts

5 contacts available for HBL Hadasit Bio Holdings. Shizune tracks 2 team members at HBL Hadasit Bio Holdings. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/hbl-hadasit-bio-holdings?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 27% |
| Medical | 2 | 18% |
| Health Care | 2 | 18% |
| Pharmaceutical | 2 | 18% |
| Biopharma | 1 | 9% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 2 | 18% |
| Seed | 1 | 9% |
| Series A | 1 | 9% |
| Series B | 1 | 9% |
| Venture - Series Unknown | 1 | 9% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Liat Hadad Simhayoff | CFO | 0 | https://shizune.co/investors/profile/liat-hadad-simhayoff |
| Rafi Hofstein | President & CEO | 0 | https://shizune.co/investors/profile/rafi-hofstein |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| KAHR medical | KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $46.5M | Venture - Series Unknown | Jun 16, 2021 |  |
| KAHR medical | KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $18M | Venture - Series Unknown | Feb 25, 2020 |  |
| Enlivex Therapeutics | Enlivex is a clinical-stage macrophage reprogramming immunotherapy company that targets diseased macrophages in patients with sepsis. The company develops an autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions such as Graft versus Host Disease (GvHD), solid organ transplant rejection, Crohn'sDisease, and other autoimmune and inflammatory disorders.The company's revolutionary approach is to induce immune tolerance by injecting apoptotic cells and facilitating their interaction with dendritic cells activates the body's innate, physiologic mechanism for down-regulating inflammation and autoimmunity.Enlivex is an Israeli-based cell immunotherapy company established in October 2005 by Professor Dror Mevorach, a world-renowned expert on clearance of dying (apoptotic) cells. | $10M |  | Apr 23, 2018 |  |
| Enlivex Therapeutics | Enlivex is a clinical-stage macrophage reprogramming immunotherapy company that targets diseased macrophages in patients with sepsis. The company develops an autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions such as Graft versus Host Disease (GvHD), solid organ transplant rejection, Crohn'sDisease, and other autoimmune and inflammatory disorders.The company's revolutionary approach is to induce immune tolerance by injecting apoptotic cells and facilitating their interaction with dendritic cells activates the body's innate, physiologic mechanism for down-regulating inflammation and autoimmunity.Enlivex is an Israeli-based cell immunotherapy company established in October 2005 by Professor Dror Mevorach, a world-renowned expert on clearance of dying (apoptotic) cells. | $8M | Series B | Sep 19, 2017 |  |
| KAHR medical | KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $2.4M |  | Sep 09, 2013 |  |
| KAHR medical | KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $3M |  | Apr 14, 2011 |  |
| ProtAb | ProtAb develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. Its first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for thetreatment of inflammatory bowel disease or IBD, ulcerative colitis or UC, and rheumatoid arthritis or RA. It operates as a subsidiary of Hadasit Bio-Holdings. HBL is a publicly traded subsidiary of Hadasit, the technology transfer company of the Hadassah University Hospital in Jerusalem in Israel. | $4M | Series A | Apr 23, 2010 |  |
| KAHR medical | KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $1.5M |  | Dec 01, 2009 |  |
| KAHR medical | KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $500K |  | Jan 28, 2009 |  |
| KAHR medical | KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. |  | Seed |  |  |

10 of 11 investments shown.

## Co-investors
- [Flerie Invest](https://shizune.co/investors/profile/flerie-invest) — VC Fund, 2 deals together
- [Korea Investment Partners](https://shizune.co/investors/profile/korea-investment-partners) — VC Fund, 2 deals together
- [Mirae Asset Venture Investment](https://shizune.co/investors/profile/mirae-asset-venture-investment) — VC Fund, 2 deals together
- [Oriella Ltd.](https://shizune.co/investors/profile/oriella-ltd) — VC Fund, 2 deals together
- [Pavilion Capital](https://shizune.co/investors/profile/pavilion-capital) — VC Fund, 2 deals together
- [Pavilion Capital](https://shizune.co/investors/profile/pavilion-capital-57b7) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [F6 Ventures](https://shizune.co/investors/profile/flat6labs) — VC Fund
- [Oqal](https://shizune.co/investors/profile/oqal) — VC Fund
- [Alesta Yatırım](https://shizune.co/investors/profile/alesta-girisim) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Middle East](https://shizune.co/investors/biotechnology-investors-middle-east)
- [Biotechnology VC Funds in Middle East](https://shizune.co/investors/biotechnology-vc-funds-middle-east)
- [Health Care Investors in Middle East](https://shizune.co/investors/health-care-investors-middle-east)
- [Health Care VC Funds in Middle East](https://shizune.co/investors/health-care-vc-funds-middle-east)
- [Health Care VC Funds in Israel](https://shizune.co/investors/health-care-vc-funds-israel)
- [Biotech Investors in Middle East](https://shizune.co/investors/biotech-investors-middle-east)

## FAQ

### What does HBL Hadasit Bio Holdings invest in?

HBL Hadasit Bio Holdings invests primarily in Biotechnology, Medical and Health Care startups, most often at Funding Round and Seed stage. Most of the 11 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact HBL Hadasit Bio Holdings?

Public channels for HBL Hadasit Bio Holdings include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at HBL Hadasit Bio Holdings?

The team at HBL Hadasit Bio Holdings includes Liat Hadad Simhayoff (CFO) and Rafi Hofstein (President & CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co